Human Naive Antibody Library
Muromonab is the first clinical-use approved antibody therapy in 1986 and the one of only four with full murine sequence. Since antibody became a major class of new drugs to treat cancer and autoimmune diseases, the disadvantages of murine-originated antibody has been extensively studied. Murine antibodies have a short therapeutic half-life in human body because they are recognized by the patient immune system as foreign proteins resulting in a human anti-mouse (HAMA) response. Subsequently, how to generate humanized antibody sequence while keeping the affinity and specificity became an important challenge in therapeutic antibody drug development.
Seeking mAb directly from human (healthy/patient) body is the most efficient solution to acquire drug-potential antibody. In the past due to the limitation of methods, it was impossible to bring this technology out of lab and enter into the industry. Developed together with phage knowledge and modern molecular biology, phage display technology enabled the possibility of mega protein library and protein engineering. Thanks to phage display technology, we are able to acquire the antibodies from all of the animal species including human ourselves.
To meet the improving demand from the bio-pharma industry, Bio Bench started to design and build its own 100-billion Human Naive Antibody Library (100-HuAb) for drug discovery. By adopting the PBMCs from 3000 healthy donors’, the size of the human naive antibody library finally reaches 220-billion clones which covering all of the antigens (10-million different types in theory). The 100-HuAb shows high germlines diversity and CDR-H3/CDR-L3 sequence diversity which is similar to nature antibody (data from IMGT database).
Low cost project? See our offer: 10-HuAb (10-billion Human Naive Antibody Library).
Seeking mAb directly from human (healthy/patient) body is the most efficient solution to acquire drug-potential antibody. In the past due to the limitation of methods, it was impossible to bring this technology out of lab and enter into the industry. Developed together with phage knowledge and modern molecular biology, phage display technology enabled the possibility of mega protein library and protein engineering. Thanks to phage display technology, we are able to acquire the antibodies from all of the animal species including human ourselves.
To meet the improving demand from the bio-pharma industry, Bio Bench started to design and build its own 100-billion Human Naive Antibody Library (100-HuAb) for drug discovery. By adopting the PBMCs from 3000 healthy donors’, the size of the human naive antibody library finally reaches 220-billion clones which covering all of the antigens (10-million different types in theory). The 100-HuAb shows high germlines diversity and CDR-H3/CDR-L3 sequence diversity which is similar to nature antibody (data from IMGT database).
Low cost project? See our offer: 10-HuAb (10-billion Human Naive Antibody Library).
Benefits and advantages
1. Full human sequence antibody, start your project with original format.
2. Low cost and reduced risk.
3. Fast, 30 - 45 days you will receive your antibody.
4. Large amount of candidate clones, up to 300+.
Specifications of the 100-HuAb
3000 healthy donors
|
100-billion clones
|
3Rs compatible
|
ScFv fragment
|
Engineered for better performance
|
Service and Time Line |
Guarantee |
Starting Material |
Deliverables |
Price |
AB210302 100-HuAb (100-billion Human Naive Antibody Library) |
Please contact Bio Bench. |
DNA/peptide/protein or related sequence. Stable cell line. NOTE: Please contact us for a detailed “list of material” regarding to your unique project. |
• Antibody sequences. • 100μg purified antibody for each clone. • QC and report. |
|
AB210303 10-HuAb (10-billion Human Naive Antibody Library) |
Please contact Bio Bench. |
DNA/peptide/protein or related sequence. Stable cell line. NOTE: Please contact us for a detailed “list of material” regarding to your unique project |
• Antibody sequences. • 100μg purified antibody for each clone. • QC and Report. |
Antibody gene diversity: a primary feature of the antibody library
Antibody sequence show high diversity among nature antibodies in all of the animal species. High sequence diversity brought higher possibility to find the right antibody for a unique antigen/epitope. To keep the diversity during naive antibody library requires leading technology and know-how technical team. Bio Bench launched a series of R&D to improve the quality of the library from the beginning, Results show the 100-HuAb is significantly high diverse in sequence.
Germlines diversity
In order to investigate the diversity of 100-HuAb, Bio Bench analyzed the sequence of antibody drugs from both approved list (till 2018) and clinical trial list (list from 2018). Data is show in Figures. The diversity of germline does not show a significant difference between 100-HuAb raised antibodies and antibody drugs.
|
|
CDR length diversity
CDR region plays the key role in determining the affinity, specificity and druggability of antibodies. High viable CDR sequence is very important CDR-H3 and CDR-L3 length and sequence are the most viable fragments among all of the 6 fragments and CDR-H3 is even far more viable than CDR-L3.
|
|
Case studies: the performances of 100-HuAb
On the platform of 100-HuAb, Bio Bench has already run 18 projects (including test projects) with therapeutic targets and 1711 clones are harvested. The amount of binders, affinity and the lead antibody functional assay are tested. Results are shown below.
Large amount of clones
The conventional hybridoma technology allows researcher to acquire 1-5 clones from each mouse and 100 mice may be killed for 300 binders with good affinity. 100-HuAb does not need any additional mouse which is totally complying with 3-R principal for animal experiment. Result shows average 100 clones will be harvested, more than 300 clones are possible under customer's demand.
High affinity
100-HuAb human naive antibody library is engineered and with 220-billion clones, then during biopanning process a large amount of clones can be harvested and the low affinity binders will be ignored. Therefore it will lead to a significantly increased amount of high affinity clones. Compare to the typical affinity range 50nM-200nM of other reported human naive antibody libraries, 17% of the binders harvested from 100-HuAb show high affinity in pM-10nM and nearly 50% of the clones are within 50nM.
|
Project M is cytokine target. After biopanning, 6 clones are selected and tested affinity according to client’s demand. These 6 clones showing high affinity range from 1.75nM to 6.07nM. |
|
|
All of the antibodies harvested from Project 039 and Project 056 are tested affinity. 4% of the antibodies show high affinity in pM level and totally 47% of the clones show affinity <50nM. |
